Table 1.
Sample information per cohort.
| BRAGGSS | DREAM | EIRA | ReAct | WTCCC | Other* | Total | |
| Sample size | 954 | 764 | 283 | 258 | 556 | 123 | 2938 |
| Sex, female % | 76 | 68 | 74 | 77 | 77 | 82 | 74 |
| Concomitant non-biologic DMARD % | 85 | 74 | 74 | 50 | 73 | 97 | 76 |
| TNF inihibitor | |||||||
| Adalimumab | 416 | 441 | 47 | 258 | 64 | 29 | 1255 |
| Certolizumab | 34 | 0 | 0 | 0 | 0 | 0 | 34 |
| Etanercept | 293 | 66 | 97 | 0 | 246 | 19 | 721 |
| Golimumab | 17 | 0 | 0 | 0 | 0 | 0 | 17 |
| Infliximab | 194 | 138 | 139 | 0 | 246 | 75 | 792 |
| Baseline disease activity, mean ( SD ) | |||||||
| DAS28-ESR4 | 6.3 (1.0) | 5.4 (1.2) | 5.3 (1.2) | 5.8 (1.0) | 6.7 (0.9) | 5.6 (1.1) | 6.0 (1.2) |
| ESR | 36.2 (26.2) | 27.7 (21.3) | 32.4 (22.9) | 31.2 (21.4) | 45.0 (28.8) | 30.2 (21.5) | 34.6 (25.4) |
| SJC | 10.1 (6.1) | 10.3 (5.5) | 9.2 (6.0) | 9.9 (5.1) | 11.8 (6.4) | 10.5 (6.3) | 10.4 (6.0) |
| TJC | 15.4 (7.3) | 10.0 (7.4) | 8.3 (6.0) | 13.1 (6.5) | 17.0 (7.3) | 10.7 (6.3) | 13.2 (7.8) |
| GHVAS | 71.0 (19.2) | 62.3 (22.1) | 56.1 (23.3) | 59.7 (20.8) | 72.6 (18.1) | 59.3 (23.9) | 66.1 (21.4) |
| 6 - month disease activity, mean ( SD ) | |||||||
| DAS28-ESR4 | 3.7 (1.6) | 3.6 (1.3) | 3.5 (1.4) | 3.7 (1.4) | 4.2 (1.5) | 3.9 (1.6) | 3.8 (1.5) |
| ESR | 22.8 (22.0) | 18.1 (16.9) | 20.0 (17.3) | 18.6 (17.0) | 27.6 (24.9) | 22.2 (19.7) | 21.8 (20.7) |
| SJC | 3.0 (4.0) | 4.8 (4.4) | 3.4 (3.8) | 3.6 (3.6) | 4.0 (4.7) | 5.0 (4.9) | 3.8 (4.3) |
| TJC | 5.0 (6.3) | 3.7 (4.6) | 3.6 (4.9) | 4.7 (5.5) | 6.3 (6.6) | 5.1 (6.1) | 4.7 (5.8) |
| GHVAS | 37.2 (25.2) | 34.5 (21.7) | 34.4 (25.2) | 31.8 (25.9) | 37.1 (25.0) | 31.8 (26.6) | 35.5 (24.5) |
* ‘Other’ displays aggregate sample characteristics for collections with sample size <100
BRAGGSS, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; DREAM, Dutch Rheumatoid Arthritis Monitoring Registry; EIRA, Swedish Epidemiological Investigation of Rheumatoid Arthritis; ESR, erythrocyte sedimentation rate; GHVAS, global health assessment rated on a visual analogue scale; ReAct, French Research in Active Rheumatoid Arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor; WTCCC, Wellcome Trust Case Control Consortium.